• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Is There a Role for Secondary Cytoreductive Surgery in Ovarian Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • It remains unclear if secondary surgery is helpful in women with recurrent ovarian cancer 
  • Harter et al. (NEJM 2021) sought to determine whether cytoreductive surgery followed by chemotherapy resulted in longer overall survival vs chemotherapy alone 

METHODS: 

  • Randomized Controlled Trial 
    • DESKTOP III Study  
  • Participants 
    • Recurrent ovarian cancer (epithelial)  
    • AGO score used to evaluate probability for complete resection  
    • Complete resection at initial surgery 
    • First relapse after a platinum-free interval of ≥6 months  
  • Interventions 
    • Secondary cytoreductive surgery followed by platinum-based chemotherapy  
    • Platinum-based chemotherapy alone
  • Study design 
    • 1:1 Randomization  
    • Required sample size based on accrual period of 3 years and a 3-year follow-up period: 408 patients would be needed | Power of 80% (assuming 10% drop out rate)  
  • Primary outcome 
    • Overall survival  
  • Secondary outcomes 
    • Quality of life at baseline, visit 1 (at 6 months), or visit 2 (at 12 months) 
    • Prognostic factors for survival  

RESULTS: 

  • Total of 407 patients  
    • Cytoreduction: 206  
    • Chemotherapy: 201 
  • Complete resection in 75.5% of cytoreduction group 
  • Median overall survival 
    • Cytoreduction: 53.7 months  
    • Chemotherapy only: 46.0 months 
    • Hazard ratio for death (HR): 0.75 (95% CI, 0.59 to 0.96); P=0.02
  • Complete resection was associated with most favorable outcome 
    • Median overall survival: 61.9 months 
  • Quality of life measures 
    • No difference between groups for global health status, quality of life, or any functional subscale  
  • Surgical complications 
    • No perioperative mortality within 30 days postop 

CONCLUSION: 

  • For women with ovarian cancer recurrence, cytoreductive surgery followed by chemotherapy resulted in longer overall survival vs chemotherapy alone 
  • The authors state 

All patients with a first relapse after a platinum-free interval of at least 6 months may be evaluated to assess whether surgery is an option 

Eligible patients could receive counseling about the options for cytoreductive surgery in centers of gynecologic oncology that have experience in surgery for relapsed ovarian cancer 

 In contrast, patients who have a high probability of incomplete resection on the basis of disease or clinical characteristics should not be exposed to a potentially harmful surgical treatment 

Learn More – Primary Sources: 

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Evaluation of the Adnexal Mass
Screening for Ovarian Cancer – Fantasy or Reality?
Ovarian or Endometrial Cancer? Consider Lynch Syndrome
USPSTF Releases Final Recommendation On Ovarian Cancer Screening

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site